Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial

IMPORTANCE: Many cancer subtypes, including KIT-mutant gastrointestinal stromal tumors (GISTs), are driven by activating mutations in tyrosine kinases and may initially respond to kinase inhibitors but frequently relapse owing to outgrowth of heterogeneous subclones with resistance mutations. KIT in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Wagner, Andrew J., Severson, Paul L., Shields, Anthony F., Patnaik, Amita, Chugh, Rashmi, Tinoco, Gabriel, Wu, Guoxian, Nespi, Marika, Lin, Jack, Zhang, Ying, Ewing, Todd, Habets, Gaston, Burton, Elizabeth A., Matusow, Bernice, Tsai, James, Tsang, Garson, Shellooe, Rafe, Carias, Heidi, Chan, Katrina, Rezaei, Hamid, Sanftner, Laura, Marimuthu, Adhirai, Spevak, Wayne, Ibrahim, Prabha N., Inokuchi, Kerry, Alcantar, Oscar, Michelson, Glenn, Tsiatis, Athanasios C., Zhang, Chao, Bollag, Gideon, Trent, Jonathan C., Tap, William D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2021
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267845/
https://ncbi.nlm.nih.gov/pubmed/34236401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.2086
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi